A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 20 Apr 2018
At a glance
- Drugs CDX-3379 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals
- 20 Apr 2018 According to a Celldex Therapeutics Inc media release, the data from this study has been presented at the American Association for Cancer Research (AACR) Annual Meeting 2018.
- 20 Apr 2018 Primary endpoint has been met. (Change in pErbB3 levels in tumor tissue), according to a Celldex Therapeutics Inc media release.
- 10 Jun 2017 Biomarkers information updated